Regeneron Pharmaceuticals, Inc.
- Jurisdiction
United States - LEI
549300RCBFWIRX3HYQ56 - ISIN
US75886F1075 (REGN )- Sectors
Scores
- Fair value (Benjamin Graham formula)
-
€644.32 33.0% undervalued - Financial strength (Piotroski F-Value)
-
4
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
5
/ 7
Profile
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. Read full profile
Fundamentals
- Net revenue
€12.12B - Gross margin
84.6% - EBIT
€3.28B - EBIT margin
27.1% - Net income
€3.80B - Net margin
31.4%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Stock price
Dividends
- Last dividend amount
-
$0.88 - Ex date
-
- Payment date
-
- Dividend payout ratio
-
4.2%
Analyst ratings
No analyst ratings available
Insider Transactions
No insider transactions in the last 90 days. View older insider transactions
Congress transactions
| Name | Transaction date | Value |
|---|---|---|
| Robert Bresnahan | June 9, 2025 | $1.00K–$15.00K |
| Byron Donalds | May 24, 2025 | $1.00K–$15.00K |
| Julie Johnson | May 14, 2025 | $1.00K–$15.00K |
| Robert Bresnahan | May 8, 2025 | $1.00K–$15.00K |
| Jefferson Shreve | May 8, 2025 | $15.00K–$50.00K |
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Andreas Halvorsen |
|
|
|
Buy |
| Peter Brown |
|
|
|
Sell |
| Ray Dalio |
|
|
|
Buy |